Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/CapsoVision, Inc./ EFFECT

SEC Filing · EFFECT

CapsoVision, Inc.

CVNASDAQEQUITYCurrent

SEC Filing

Filed Aug 21, 2026Accepted Aug 24, 2026, 12:15 AM EDTCIK 1378325Accession 9999999995-26-002734
View company →Permanent SEC source ↗
Share

Company context

We are a global commercial-stage medical technology company focused on creating diagnostic and screening products to identify abnormalities of the GI tract. We develop advanced imaging and AI technologies in creating such products while maximizing the flexibility, convenience, profitability, and safety of patient care. We are a Delaware company, incorporated in 2005. Our corporate headquarters is located in Saratoga, California.

Current securities

CVNASDAQ · EQUITY · Current

Recent company filings

  1. Other EventsSep 28, 2026
  2. 4 filingSep 23, 2026
  3. Entry into a Material Definitive AgreementSep 18, 2026
  4. 424B5 filingSep 18, 2026
  5. 424B5 filingAug 21, 2026

As-filed source

Primary evidence
As filedOpen full document ↗